The study of sleep apnea syndrome with nasal obstruction

The study of sleep apnea syndrome with nasal obstruction - The study of nasal obstruction

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000026368

Enrollment

100

Registered

2017-03-02

Start date

2013-09-27

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sleep apnea syndrome

Interventions

The following each treatment for 14days 1.Fexofenadine Hydrochloride(60mg) twice daily 2.Fexofenadine Hydrochloride(60mg)/ Pseudiephedrine Hydrochloride(120mg) Combination Tablets twice daily

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients who diagnosed with SAS and started CPAP therapy have nasal obstruction for allergic rhinitis.

Exclusion criteria

Exclusion criteria: severe nasal septal space disease severe nasal polyps severe nasal tumor Uncontrolled hypertension Severe coronary artery disease Narrow angle glaucoma

Design outcomes

Primary

Measure	Time frame
1.The chages of nasal obstruction in patients with OSAS after treatment 2.Serum total IgE, RAST 3.The persistence of CPAP treatment (using time etc.) 4.The questionnaire of Pittsburg Sleep Quality Index(PSQI) 5.Epworth sleepness scale(ESS)	—

Countries

Japan

Contacts

Public ContactWakako Yamasawa

Department of Medicine, Keio University School of Medicine Pulmonary Medicine

wakako@df6.so-net.ne.jp0333531211

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026